Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal?

Stern, Sam J; D'Orazio, Joseph L; Work, Brian D; Calcaterra, Susan L; Thakrar, Ashish P

Stern, Sam J; D'Orazio, Joseph L; Work, Brian D; Calcaterra, Susan L; Thakrar, Ashish P.

Afiliación

Stern SJ; Division of Hospital Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
D'Orazio JL; Lewis Katz School of Medicine, Center for Urban Bioethics, Philadelphia, Pennsylvania, USA.
Work BD; Cooper Center for Healing, Camden, New Jersey, USA.
Calcaterra SL; Department of Emergency Medicine, Division of Toxicology and Addiction Medicine, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
Thakrar AP; Division of Hospital Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.

J Hosp Med ; 19(4): 339-343, 2024 Apr.

Article en En | MEDLINE | ID: mdl-38030816

Asunto(s)

Buprenorfina; Síndrome de Abstinencia a Sustancias; Humanos; Analgésicos Opioides/efectos adversos; Síndrome de Abstinencia a Sustancias/tratamiento farmacológico; Buprenorfina/uso terapéutico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Abstinencia a Sustancias / Buprenorfina Límite: Humans Idioma: En Revista: J Hosp Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google